RNA-based immunotherapy for glioblastoma using engineered CAR NK cells
Innovative RNA technology aims to enhance innate immunity against glioblastoma by silencing NKG2D in NK cells using siRNA, potentially transforming tumor microenvironments and improving therapeutic outcomes.